Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Karyopharm reports robust revenue growth and strategic clinical advancements

Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.
Strategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.
Challenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.
Overall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.

Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations

Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.
The company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.
Opportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.

Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues

Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.

Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects

Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.
Promising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.
Challenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.

Karyopharm meets revenue targets, eyes transformative outcomes in trials

Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.
While facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.
With a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.
Overall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.

Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing

Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options

Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call Transcript

NEWTON, Mass., Aug. 5, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2021.

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results

The stock price of Karyopharm Therapeutics Inc. (Nasdaq: KPTI) increased by over 7% pre-market. This is why it happened.

KPTI Stock Price Increases Over 7% Pre-Market: Why It Happened

NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021

NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

Peabody Energy

Crestwood Equity Partners

Corvus Pharmaceuticals

CuriosityStream

Energy Transfer LP Unit

FuboTV

Genco Shipping & Trading

Helix Energy Solutions Group

H&R Block

Jewett-Cameron Trading

Tenet Fintech Group Inc

Palantir Technologies

Amplify Junior Silver Miners ETF

Schlumberger

SPDR S&P 500 ETF Trust

TransGlobe Energy

At the mid-year mark, our contributors give updates on their picks.

SA Marketplace 2021 Top Idea Contest: Mid-Year Update

SHANGHAI  and  HONG KONG , July 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd), or in combination with dexamethasone (Xd) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM); and as monotherapy in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma (rrDLBCL), including DLBCL arising from follicular lymphoma, who have received at least two lines of systemic therapy. Antengene has submitted New Drug Applications (NDAs) for selinexor in multiple Asia Pacific markets including China, Australia, South Korea, and Singapore, and was granted Priority Review status by China's National Medical Products Administration (NMPA) and Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea (MFDS).

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

SHANGHAI and HONG KONG, July 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, recently announced that China's National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for single agent selinexor, a first-in-class orally available Exportin 1 (XPO1) inhibitor, for the treatment of patients with myelofibrosis (MF) in China. MF is a clonal hematologic neoplasm which can emerge either as primary MF, polycythemia vera (PV) or essential thrombocythemia (ET)[1].

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and for the clinical development of Karyopharm's other programs, including eltanexor.

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

I list 8 potential reasons the stock is down despite approvals. SIENDO is a major binary event for the stock.

Karyopharm: Why Is It Down, And What Should Take It Back Up

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS). Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association (EHA) 2021 Virtual Congress taking place June 9-17, 2021.

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), announced updated data of eltanexor for the treatment of patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. This Phase I/II study evaluated single-agent eltanexor in patients with higher-risk MDS, ie, high-risk or intermediate-2 MDS by the International Prognostic Scoring System (IPSS) and 5%-19% myeloblasts.

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management changes to its commercial organization, including the appointment of Sohanya Cheng, MBA, as Senior Vice President of Sales and Commercial Operations.

Karyopharm Announces Key Changes to Its Commercial Leadership Team

NEWTON, Mass., June 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, are now commercially available.

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

NEWTON, Mass., June 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

NEWTON, Mass., May 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 9:30 a.m.

Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference

NEWTON, Mass., May 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

BioNTech SE

Connect Biopharma Holdings

Fulgent Genetics

GlaxoSmithKline

Knnate Biopharma

Legend Biotech

aTyr Pharma

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

SHANGHAI and HONG KONG, May 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor (XPOVIO®) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). Endometrial cancer is a common gynecologic malignancy which frequently occurs in women of reproductive age.

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China, added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of relapsed myeloma.

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call Transcript

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.00% and -12.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.

News for Karyopharm Therapeutics Stock (KPTI)